Medtronic reported 4.1% organic revenue growth and 6.2% adjusted EPS growth. See why we upgraded MDT stock to 'Buy' with a ...

The platform, which includes the new form factor CGM and the Simplera Sync sensor, is designed for integration with Medtronic ...

Medtronic’s third quarter also marked a return to growth for its Diabetes unit in the United States, with the global adoption of the MiniMed 780G system driving performance. This trend is also ...

Medtronic: Long-Awaited FDA Approval of 780g Pump Should Return Diabetes Unit to Growth Wide-moat Medtronic received highly welcome news today as the U.S. Food and Drug Administration has (finally ...

For me, diabetes is arguably the division that has the greatest room to grow thanks to Medtronic's MiniMed 780G system, which has only two major competitors - Dexcom's (DXCM) G7 continuous glucose ...

Medtronic chairman and CEO. The company's Diabetes segment showed notable improvement, with revenue increasing 10.4% organically. This was attributed to the continued adoption of the MiniMed 780G ...

Medtronic plc MDT reported adjusted earnings ... U.S. revenues grew mid-single digits on the continued adoption of the MiniMed 780G automated insulin delivery system, with an increase in the ...

Medtronic has issued an “Urgent Medical Device Correction” about the accuracy of insulin pump delivery during changes in air pressure, such as airplane takeoffs and landings. “We request you ...

Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. Log out ...

Actual results may differ materially from anticipated results. Medtronic does not undertake to update its forward-looking statements or any of the information contained in this press release ...

Medtronic's surgical device sales decline due to inventory issues CEO Martha monitors impact of Trump's tariffs Shares down more than 7% in morning trade Feb 18 (Reuters) - Medtronic (MDT.N ...